<?xml version='1.0' encoding='utf-8'?>
<document id="28213005"><sentence text="Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study."><entity charOffset="3-17" id="DDI-PubMed.28213005.s1.e0" text="clarithromycin" /></sentence><sentence text="Clarithromycin may improve cachexia and survival in non-small cell lung cancer (NSCLC), but adequately controlled data are lacking"><entity charOffset="0-14" id="DDI-PubMed.28213005.s2.e0" text="Clarithromycin" /></sentence><sentence text=" This study was undertaken primarily to inform the feasibility and scale of a phase III trial" /><sentence text=" Eligible consenting patients with stage IV NSCLC and cachexia were to be randomized to receive either clarithromycin 250mg twice daily or placebo for eight weeks"><entity charOffset="103-117" id="DDI-PubMed.28213005.s4.e0" text="clarithromycin" /></sentence><sentence text=" Aspects of trial feasibility recorded included numbers eligible, approached and recruited, together with adherence and completion of treatment and assessments" /><sentence text=" Over 6 months, none of 125 patients identified fulfilled the entry criteria" /><sentence text=" The commonest reasons for ineligibility were the use of an excluded concurrent drug (45, 36%), brain metastases (22, 18%), poor performance status (21, 17%) and current chemotherapy (15, 12%)" /><sentence text=" A phase III trial of clarithromycin using these entry criteria is not feasible in this setting"><entity charOffset="22-36" id="DDI-PubMed.28213005.s8.e0" text="clarithromycin" /></sentence><sentence text=" Other macrolides that have a lower risk of a drug-drug interaction may be more practical to pursue" /><sentence text="" /></document>